Key facts
- This page summarizes Paige Mahaney's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Feb 2025, 16:54.
Paige Mahaney - 14 Feb 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- CCCC
- Reported as of
- 14 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2025, 16:54:38 UTC
- Prior SEC filing
- 29 Oct 2024
- Next SEC filing
- 30 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shagha Russell, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paige Mahaney filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 18 Feb 2025.
Change
- Previous filing in this sequence was filed on 29 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CCCC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +28,200
- Change %
- +37%
- Price
- $0.000000
- Shares after
- 105,000
- Date
- 14 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CCCC
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +42,400
- Change %
- Price
- $0.000000
- Shares after
- 42,400
- Date
- 14 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,400
- Exercise price
- $3.18
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.
Footnote F2
The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.